<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Mitoguazone (<z:chebi fb="0" ids="17158">methylglyoxal</z:chebi> bisguanylhydrazone, <z:chebi fb="36" ids="29309">methyl</z:chebi>-GAG or MGBG) is a synthetic polycarbonyl derivative with activity in patients with Hodgkin's and non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:e sem="disease" ids="C0278996" disease_type="Neoplastic Process" abbrv="">head and neck cancer</z:e>, <z:hpo ids='HP_0012125'>prostate cancer</z:hpo>, and <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Mitoguazone has also recently been documented to have activity in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-related <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Among anticancer drugs, mitoguazone has a unique mechanism of action via interference with the <z:chebi fb="0" ids="51349">polyamine</z:chebi> biosynthetic pathway </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="51349">Polyamines</z:chebi> stabilize DNA structure by non-covalent cross-bridging between phosphate groups on opposite strands </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, mitoguazone causes uncoupling of oxidative phosphorylation </plain></SENT>
<SENT sid="5" pm="."><plain>In this study, the ability of mitoguazone to induce <z:mpath ids='MPATH_3'>apoptosis</z:mpath> by inhibiting the <z:chebi fb="0" ids="51349">polyamine</z:chebi> pathway was assessed in three Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines (Raji, Ramos and Daudi) and one prostate <z:mp ids='MP_0002038'>carcinoma</z:mp> cell line (MPC 3) </plain></SENT>
<SENT sid="6" pm="."><plain>Additional evaluations were performed in two human <z:hpo ids='HP_0003002'>breast cancer</z:hpo> cell lines (MCF7 with <z:mp ids='MP_0002169'>wild-type</z:mp> p53 and VM4K with mutated p53) to determine whether the p53 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene was required for efficient <z:mpath ids='MPATH_3'>apoptosis</z:mpath> induction </plain></SENT>
<SENT sid="7" pm="."><plain>The present study demonstrated that mitoguazone induces <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:hpo ids='HP_0000001'>all</z:hpo> the different human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines tested in a concentration- and time-dependent way, and triggers a p53-independent programmed cell <z:hpo ids='HP_0011420'>death</z:hpo> in the human <z:hpo ids='HP_0003002'>breast cancer</z:hpo> MCF7 cell line </plain></SENT>
</text></document>